tamoxifen

Postoperatively, the patient received TC(docetaxel+cyclophosphamide) chemotherapy, total breast irradiation, and tamoxifen for 10 years. Considering the different subtypes and absence of other lesions, the patient was considered to have latent breast cancer as a new lesion. Chemotherapy, including anti- HER2 therapy, radiotherapy, and endocrine therapy, was administered as adjuvant treatment.

Postoperatively, the patient was started on tamoxifen, and she remains recurrence-free to date. This case underscoring the importance of careful pre-treatment assessment of malignancy.

Postoperatively, tamoxifen, a CDK4/6 inhibitor, and radiotherapy were administered...Despite initiating weekly paclitaxel plus bevacizumab, the disease progressed rapidly, and she died 4 months later. Notably, OMS symptoms did not recur. This case highlights paraneoplastic OMS as an initial manifestation of breast cancer, with neurological improvement following systemic therapy.

P3, N=4800, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.

P2, N=90, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jun 2026 --> Jan 2025

Here, we compare adenovirus-delivered Cre with tamoxifen-inducible CreER systems in models targeting luminal mammary epithelial cells for p53-loss...Despite similar tumor latencies across induction strategies, our findings demonstrate that adenoviral infection exerts long-term immunological effects that can confound interpretation of immune dynamics during early mammary tumorigenesis. These results emphasize the importance of induction-method selection when using genetically engineered mouse models to study cancer-immune interactions.

P2, N=600, Not yet recruiting, Eli Lilly and Company | Trial completion date: Jan 2029 --> Dec 2029

P3, N=123, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | N=2032 --> 123 | Trial completion date: Mar 2032 --> Oct 2030

P2, N=24, Active, not recruiting, University of Miami | Recruiting --> Active, not recruiting | N=500 --> 24

This study provides the first human evidence with long-term ET administration to reveal that, besides genetic profiles, the gut microbiota is another critical factor that we should consider in the influence and prediction of breast cancer recurrence in the future.

Treatment principles for MBC mirror those of female breast cancer and include mastectomy, endocrine therapy (tamoxifen), radiotherapy, and systemic therapy as indicated...This case highlights the rarity of EPC with a mixed invasive component in men and underscores the importance of comprehensive morphologic and immunophenotypic evaluation. Increased reporting of such cases will improve understanding and management of male breast malignancies.

In this study, CA800-PR was newly developed for the treatment of hormone receptor-positive breast cancer unlike conventional drugs such as tamoxifen and aromatase inhibitors...Comparing with the traditional hormone therapies aimed at controlling tumor growth or preventing recurrence post-surgery, the tumor-targeted NIR fluorescent dye CA800-PR alone can be effectively used as a multifunctional antitumor agent directly inducing apoptosis in both MCF-7 cells and xenograft tumors. This work provides a promising alternative to hormone therapy-related breast cancer for future clinical applications.